Is SUPN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

486 people get SUPN articles and Market Currents by email alert.

Get email alerts on SUPN »

HEADLINES:

Supernus to Present at Two Investor Conferences

GlobeNewswire (Mon, 4:30PM)
Supernus Pharmaceuticals Reports First Quarter 2013 Financial Results

GlobeNewswire (May 13, 2013)
Supernus Announces First Quarter 2013 Earnings Conference Call and Webcast

GlobeNewswire (May 6, 2013)
Supernus Announces Closing of $90 Million of 7.50% Convertible Senior Secured Notes Due 2019

GlobeNewswire (May 6, 2013)
Supernus Secures Financing For CNS Pipeline Development
Bay Area Biotech • Sun, May 5
Supernus Prices Offering of $75 Million of 7.50% Convertible Senior Secured Notes Due 2019

GlobeNewswire (Apr 26, 2013)
Supernus Announces Proposed Offering of $75 Million of Convertible Senior Secured Notes

GlobeNewswire (Apr 24, 2013)
March Shows Solid IPO Momentum Into April
IPO Candy • Tue, Apr 9 • 1 Comment
Small Pharma Watch List: Week Of April 8, 2013
Chemistfrog • Mon, Apr 8 • 8 Comments
Supernus: Record For Worst Launch In Recent History?
Brian L. Wilson • Tue, Mar 26 • 8 Comments
Rockwell May Rise On Positive Phase III Results In July
Neil Danics • Thu, Mar 21 • 1 Comment
Supernus Pharmaceuticals' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 14
Supernus Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Financial Results

GlobeNewswire (Mar 14, 2013)
Supernus Announces Year-End and Fourth Quarter 2012 Earnings Conference Call and Webcast

GlobeNewswire (Mar 7, 2013)
Supernus Launches Oxtellar XR(TM) in the United States

GlobeNewswire (Feb 1, 2013)
Small Pharma Watch List: Week Of January 21st
Chemistfrog • Tue, Jan 22 • 16 Comments
Supernus Pharmaceuticals Readying For A Super Year Ahead
Chemistfrog • Wed, Jan 16 • 2 Comments
Supernus Appoints Victor Vaughn as Senior Vice President of Sales

GlobeNewswire (Jan 14, 2013)
Recent Small Pharma Offerings Create Tempting Current Entries
Chemistfrog • Fri, Dec 21, 2012 • 2 Comments
Favorable AcelRx Stock Offering Price May Catalyze The Company's Share Price
Chemistfrog • Fri, Dec 7, 2012 • 3 Comments

To learn more about Seeking Alpha Pro, click here.

Supernus Secures Financing For CNS Pipeline Development
Bay Area Biotech • Sun, May 5
Supernus: Record For Worst Launch In Recent History?
Brian L. Wilson • Tue, Mar 26 • 8 Comments
Supernus Pharmaceuticals Readying For A Super Year Ahead
Chemistfrog • Wed, Jan 16 • 2 Comments
After 2 Drug Approvals, Can Supernus Deliver In 2013?
C.R. Jackson • Mon, Nov 26, 2012 • 3 Comments
Obesity Drug Approvals - A Hidden Winner In Supernus
Red Acre Investments • Thu, Jul 19, 2012 • 33 Comments
Supernus Pharma: A Recent IPO Awaiting Pair Of FDA Decisions
Mike Havrilla • Tue, Jun 12, 2012 • 3 Comments
IPO Preview: Supernus Pharmaceuticals
IPOdesktop • Tue, Apr 24, 2012 • 2 Comments

March Shows Solid IPO Momentum Into April
IPO Candy • Tue, Apr 9 • 1 Comment
Small Pharma Watch List: Week Of April 8, 2013
Chemistfrog • Mon, Apr 8 • 8 Comments
Rockwell May Rise On Positive Phase III Results In July
Neil Danics • Thu, Mar 21 • 1 Comment
Small Pharma Watch List: Week Of January 21st
Chemistfrog • Tue, Jan 22 • 16 Comments
Recent Small Pharma Offerings Create Tempting Current Entries
Chemistfrog • Fri, Dec 21, 2012 • 2 Comments
Favorable AcelRx Stock Offering Price May Catalyze The Company's Share Price
Chemistfrog • Fri, Dec 7, 2012 • 3 Comments
ACRX Falls On Financing, Creating Opportunity Ahead Of Phase III Data
PropThink • Thu, Dec 6, 2012
Small Pharmaceuticals With Near Term Catalysts Offer Investment Opportunities
Chemistfrog • Tue, Dec 4, 2012 • 12 Comments
Applying The Venture Capital Model To Public Companies: Hugh Cleland
Life Sciences Report • Wed, Nov 21, 2012 • 2 Comments
A Small Pharma Blogger's Trading Portfolio
Chemistfrog • Thu, Oct 4, 2012 • 6 Comments
Acadia Pharmaceuticals Poised For 100% Gain By December
Red Acre Investments • Mon, Sep 10, 2012 • 29 Comments
5 Bio-Pharma Stocks To Buy Right Here
Joe Springer • Fri, Aug 24, 2012 • 28 Comments
Cramer's Mad Money - Which 2012 IPOs Are Worth Buying Or Selling? (7/19/12)
SA Editor Miriam Metzinger • Fri, Jul 20, 2012 • 3 Comments
Vivus Vs. Citron, Buy Vivus
Rx Stocks • Fri, Jul 20, 2012 • 106 Comments
3 Pharmaceutical Stocks Making Big Moves On Wednesday July 18th
Markus Aarnio • Thu, Jul 19, 2012 • 7 Comments
2012 Biotech IPOs: Age Of The Dreamers?
Bioassociate Consulting • Wed, Jul 4, 2012
2 Riskier Pharma Plays For The Aggressive Investor
Matt Schilling • Fri, Jun 29, 2012 • 13 Comments
2 Drug Stocks To Consider In The Coming Days
Matt Schilling • Wed, Jun 27, 2012 • 5 Comments
Russell 3000 U.S. Healthcare Additions For June 2012
EXPstocktrader • Mon, Jun 11, 2012 • 2 Comments
Facebook's May Losses Exhaust IPO Market
Kevin Quon • Sun, Jun 10, 2012 • 4 Comments

Supernus Pharmaceuticals' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 14

Supernus to Present at Two Investor Conferences

GlobeNewswire (Mon, 4:30PM)
Supernus Pharmaceuticals Reports First Quarter 2013 Financial Results

GlobeNewswire (May 13, 2013)
Supernus Announces First Quarter 2013 Earnings Conference Call and Webcast

GlobeNewswire (May 6, 2013)
Supernus Announces Closing of $90 Million of 7.50% Convertible Senior Secured Notes Due 2019

GlobeNewswire (May 6, 2013)
Supernus Prices Offering of $75 Million of 7.50% Convertible Senior Secured Notes Due 2019

GlobeNewswire (Apr 26, 2013)
Supernus Announces Proposed Offering of $75 Million of Convertible Senior Secured Notes

GlobeNewswire (Apr 24, 2013)
Supernus Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Financial Results

GlobeNewswire (Mar 14, 2013)
Supernus Announces Year-End and Fourth Quarter 2012 Earnings Conference Call and Webcast

GlobeNewswire (Mar 7, 2013)
Supernus Launches Oxtellar XR(TM) in the United States

GlobeNewswire (Feb 1, 2013)
Supernus Appoints Victor Vaughn as Senior Vice President of Sales

GlobeNewswire (Jan 14, 2013)
Supernus Announces Pricing of Public Offering

GlobeNewswire (Nov 29, 2012)
Supernus Announces Positive Phase IIb Results on SPN-810 and Decision to Advance to Late Stage Development

GlobeNewswire (Nov 20, 2012)
Supernus Receives Three Years of Market Exclusivity for Oxtellar XR(TM)

GlobeNewswire (Nov 19, 2012)
Supernus Pharmaceuticals Reports Third Quarter 2012 Financial Results

GlobeNewswire (Nov 7, 2012)
Supernus Announces Issuance of Two Patents Covering Trokendi XR(TM)

GlobeNewswire (Nov 5, 2012)
Supernus Announces Resignation of Board Member

GlobeNewswire (Oct 31, 2012)
Supernus Receives FDA Approval for Oxtellar XR(TM) in Epilepsy

GlobeNewswire (Oct 22, 2012)
Supernus to Present at Two Investor Conferences in September 2012

GlobeNewswire (Aug 29, 2012)
Supernus Pharmaceuticals Reports Second Quarter 2012 Financial Results

GlobeNewswire (Aug 10, 2012)
Supernus Appoints Dr. Stefan Schwabe, MD, PhD as Exec. VP R&D and Chief Medical Officer

GlobeNewswire (Jul 20, 2012)

SUPN vs. ETF Alternatives

Company Description

We are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. Our extensive expertise in product development has been built over the past 20 years: initially as a stand alone development organization,... More

Sector: Healthcare

Industry: Drugs - Generic

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Monday, May 13, 4:07 PM Supernus Pharmaceuticals (SUPN): Q1 EPS of -$0.60 beats by $0.11. Revenue of $147K misses by $423K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, April 26, 11:53 AM Supernus Pharmaceuticals (SUPN +10.6%) moves up after pricing its $75M offering of convertible senior secured notes due 2019. The company intends to use approximately $21M million of the net proceeds to repay in full its borrowings under and terminate its secured credit facility and the remainder of the net proceeds to fund the commercialization of its approved and tentatively approved drugs, Oxtellar XR and Trokendi XR, and to continue development of its pipeline. Comment! [Healthcare, On the Move]
Wednesday, April 24, 6:03 PM Supernus Pharmaceuticals (SUPN) announces a private offering of $75M in Convertible Senior Notes due 2019, with a 30-day option to purchase up to an additional $15M. The notes are being secured by liens on substantially all of SUPN's assets. Shares -14% AH. Comment! [Healthcare, On the Move]
Wednesday, April 24, 5:52 PM After-hours top gainers, as of 5:15 p.m.: AKAM +16%. FIO +12%. AVG +10%. ANGI +8%. BYI +6%.
After-hours top losers: SUPN -14%. CTXS -12%. EQIX -11%. INTU -10%. ZNGA -8%. Comment! [On the Move]
Tuesday, March 26, 5:45 PM After-hours top gainers, as of 5:15 p.m.: MXWL +9%. SAI +4%. OWW +3%. SPLK +3%. SUPN +3%.
After-hours top losers: LNDC -8%. ACMP -4%. EOG -4%. PXD -3%. LOGM -3%. 1 Comment [On the Move]
Thursday, March 14, 4:57 PM Supernus Pharmaceuticals (SUPN): Q4 EPS of -$0.51 beats by $0.20. Revenue of $1.09M. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
Friday, November 30, 2012, 1:04 PM Midday top 10 gainers: MARK +38%. MITL +30%. MHH +25%. CBK +24%. PPHM +24%. AMPL +24%. TELK +19%. PLNR +17%. TLAB +15%. FIVE +15%.
Top 10 Losers: RIC -24%. NTLS -23%. FFKY -19%. SUPN -18%. SBLK -14%. VRSN -14%. PSUN -14%. MMYT -13%. HGSH -13%. PWX -11%. Comment! [On the Move]
Friday, November 30, 2012, 7:45 AM Supernus Pharmaceuticals (SUPN) dives 16% after pricing a 6M secondary at just $8/share. The stock was trading at $11 late yesterday afternoon. (PR) Comment! [Healthcare, On the Move]
Monday, October 22, 2012, 1:38 PM Supernus Pharmaceuticals (SUPN) jumps at the open but gives back the entire gain, despite receiving approval from the FDA for its epilepsy treatment, Oxtellar XR, a once-daily extended release formulation of oxcarbazepine. The FDA also granted a waiver for the pediatric study requirement for ages birth to one month and a deferral for submission of post-marketing assessments for children one month to 6 years of age. Comment! [Healthcare]
Monday, October 22, 2012, 9:10 AM Premarket gainers: PGRX +42%. SUPN +16%. SVU +7%. ACOM +8%. OREX +7%. NBG +6%. BTU +6%. PHG +6%. GIVN +6%.
Losers: OSG -50%. NXY -7%. Comment! [On the Move]
Wednesday, June 27, 2012, 9:05 AM Premarket gainers: ENTR +25%. AMRN +15%. SUPN +8%. WPRT +8%.
Losers: ORLY -17%. OMER -16%. CCG -6%. Comment! [On the Move]
Tuesday, June 26, 2012, 9:10 AM Premarket gainers: SUPN +38%. SCMF +12%. NWSA +7%. APOL +6%.
Losers: JRCC -8%. LDK -7%. Comment! [On the Move]
Tuesday, June 26, 2012, 8:28 AM Supernus (SUPN) soars 40% after it receives tentative FDA approval for its Trokendi XR treatment for epilepsy. Final authorization is conditional on Supernus resolving a marketing exclusivity issue regarding a specific pediatric population. The FDA also denies a Citizen's Petition filed in 2011 by Upsher Smith Labs related to its NDA on Trokendi XR. Comment! [Healthcare, On the Move]

Chemistfrog
$SUPN I believe entry down here is wise. Q1 financials could really give the company momo.. Final approval for Trokendi in June/July
Apr 20, 7:48 PM
Reply (2)

• !Report Abuse
View all 2 replies
joe kelly: You have any opinion on cytk? Keeps coming up on my radar along with supn.
Apr 20, 8:05 PM
• !Report Abuse
Chemistfrog: $CYTK chart is in breakout mode. Many catalysts ahead for 13. Watch earnings release for phase IIb update.. I like the company. Good future.
Apr 20, 9:00 PM
• !Report Abuse
Add a reply...

140 characters

gohsi
$SUPN <200M market cap + 1 product on market + 1 product which will soon has FDA approval + nice pipeline... I think it is a good buy now
Mar 17, 11:34 PM
Reply (1)

• !Report Abuse
View all 1 replies
jimbo-hawks: around what time is FDA approval?
Mar 18, 4:58 PM
• !Report Abuse
Add a reply...

140 characters

reachmygoals1
i expect a nice run up SUPN before october 19th, fda decision.
10/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/MAjrXs Premarket gainer $ENTR (23%), $AMRN(11.32%), $SUPN(8%), $PWRD(5%)
6/27/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Chemistfrog
$SUPN I believe entry down here is wise. Q1 financials could really give the company momo.. Final approval for Trokendi in June/July
Apr 20, 7:48 PM
Reply (2)

• !Report Abuse
View all 2 replies
joe kelly: You have any opinion on cytk? Keeps coming up on my radar along with supn.
Apr 20, 8:05 PM
• !Report Abuse
Chemistfrog: $CYTK chart is in breakout mode. Many catalysts ahead for 13. Watch earnings release for phase IIb update.. I like the company. Good future.
Apr 20, 9:00 PM
• !Report Abuse
Add a reply...

140 characters

gohsi
$SUPN <200M market cap + 1 product on market + 1 product which will soon has FDA approval + nice pipeline... I think it is a good buy now
Mar 17, 11:34 PM
Reply (1)

• !Report Abuse
View all 1 replies
jimbo-hawks: around what time is FDA approval?
Mar 18, 4:58 PM
• !Report Abuse
Add a reply...

140 characters

SUPN Supernus Pharmaceuticals, Inc.

SUPN

Supernus Pharmaceuticals, Inc.